Effects of H5 (20 and 40 mg/kg, p.o.), and diazepam (2.5 mg/kg, i.p.) in the Rota-rod test in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice. by Sheona Watson-Scales (586942)

NEDD4 knockout decreases IFITM3 ubiquitination and protects cells from virus infection. by Nicholas M. Chesarino (781971)

Total plasma cortisol concentration over time following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin or 3.0 mg/kg ketoprofen in 6-d... by Emma Nixon (11772946)

Subjects:

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Decreased Fhl1b activity augments induction of pancreatic endocrine cells. by Jin Xu (31283)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Decreased expression levels of the MYO6 protein in <i>ksv</i> mice. by Yuta Seki (4385833)

“…Expression of MYO6 is completely ablated in the hair cells of <i>Myo6</i>^-/- mice (C). Scale bar = 5 μm. D and E. Western blot analysis of homogenates prepared from the inner ears of +/+, +/<i>ksv</i> and <i>ksv/ksv</i> mice at P30 detected with anti-MYO6 (N-ter, D) and MYO6 (C-ter, E) antibodies (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183477#pone.0183477.s007" target="_blank">S2 Table</a>). …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects: